bluebird bio Inc at Bank of America Global Healthcare Conference Transcript
We're going to get going here with our next company presenter at the BofA Annual Healthcare Conference. My name is Jason Gerberry. I'm one of the biotech analysts, and I'm pleased to be introducing our next company presenter, bluebird bio. We've got with us Andrew Obenshain, CEO; and Tom Klima, Chief Commercial Officer. So gentlemen, first off, thanks for joining us.
Thank you. Thanks for having us.
Questions & Answers
So bluebird is a company in effectively developing functional cures, gene therapies for complex and rare diseases. And you're now kind of at a point where you're pivoting from an R&D stage company to a commercial stage company, you've got 2 approved gene therapies, one on the way filed for -- what do you think, your biggest market opportunity in
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |